New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

7

It’s time to address the shifting tides of content in pharma

A consistent theme from SXSW is the downturn of brand advertising. Consumers don’t want to feel marketed to but are open to content that is entertaining or provides some value exchange. Value is not a new concept, as content marketing has been a consistent tactic for a long time. But more often we see consumers’ ability to block or tune out brand content. Couple this with the fact that content looks much different than it did even a few years ago, and it’s clear that this is an area where pharma needs to innovate.

8

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

AbbVie Inc. and Landos Biopharma, Inc. today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.

10

J&J wins FDA nod for pulmonary arterial hypertension combo pill

The combo pill is indicated for chronic use in pulmonary arterial hypertension (PAH) patients falling under the World Health Organization’s functional classes II to III. These classes include patients who may have no symptoms at rest but experience shortness of breath or discomfort during normal activities such as climbing stairs or running errands.